Kompenzují nové léky vliv cytogenetických negativních prognostických markerů u pacientů s mnohočetným myelomem?
| Title in English | Do the "new drugs" antagonize the impact of unfavourable cytogenetic markers in multiple myeloma? |
|---|---|
| Authors | |
| Year of publication | 2007 |
| Type | Article in Proceedings |
| Conference | Sborník abstrakt, XXI. Olomoucké hematologické dny s mezinárodní účastí |
| MU Faculty or unit | |
| Citation | |
| Field | Genetics and molecular biology |
| Keywords | multiple myeloma; "new drugs"; cytogenetics; cIg FISH |
| Description | In our study, we have concentrated on four aberrations in multiple myeloma (MM) malignant plasma cells: deletions of tumor suppressor genes RB (locus 13q14) and p53 (17q13), translocation involving IGH gene t(4;14), and actually focused amplification of CKS1B gene in 1q21 locus. All of these aberrations are known as negative prognostic factors in patients (pts) treated by conventional therapy or stem cell transplantation. The aim of this study is to show if these selected aberrations act as negative prognostic factors also in patients treated by Velcade or by thalidomide, new drugs used in relapsed patients. In our group of patients, no one of monitored aberrations seems to have any impact, neither positive nor negative, on efficiency of used treatment. It is possible that new drugs, Velcade and thalidomide, antagonize the impact of cytogenetic negative prognostic factors in relapsed patients with MM. |
| Related projects: |